0001179110-21-003441.txt : 20210315
0001179110-21-003441.hdr.sgml : 20210315
20210315202803
ACCESSION NUMBER: 0001179110-21-003441
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210315
FILED AS OF DATE: 20210315
DATE AS OF CHANGE: 20210315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Keson-Brookes Maiken
CENTRAL INDEX KEY: 0001693805
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38586
FILM NUMBER: 21743232
MAIL ADDRESS:
STREET 1: 35 OAK HILL ROAD
CITY: FAYVILLE
STATE: MA
ZIP: 01745
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Rubius Therapeutics, Inc.
CENTRAL INDEX KEY: 0001709401
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 042688109
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 399 BINNEY STREET, SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-679-9600
MAIL ADDRESS:
STREET 1: 399 BINNEY STREET, SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2021-03-15
0
0001709401
Rubius Therapeutics, Inc.
RUBY
0001693805
Keson-Brookes Maiken
C/O RUBIUS THERAPEUTICS, INC.
399 BINNEY STREET, SUITE 300
CAMBRIDGE
MA
02139
0
1
0
0
CLO & Corp. Secretary
Common Stock
2021-03-15
4
M
0
25000
7.70
A
25000
D
Common Stock
2021-03-15
4
S
0
25000
20.2386
D
0
D
Stock Option (Right to Buy)
7.70
2021-03-15
4
M
0
25000
0
D
2029-11-28
Common Stock
25000
225000
D
The sale was effected pursuant to a Rule 10b5-1 trading plan, effective January 15, 2020, adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.69, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
25% of this option vested on November 18, 2020, then in 12 equal quarterly installments thereafter.
/s/ Joanne M. Protano, Attorney-in-Fact
2021-03-15